- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Aripiprazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 1
- States / cities
- Wallingford, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 1,651
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Parkinson Disease
- Interventions
- Cannabidiol, Placebo
- Drug · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Schizophrenia, Cannabis Dependence, Prodromal for Psychotic Illness, Family History of Alcoholism, Healthy Control, Opioid-use Disorder, Post Traumatic Stress Disorder
- Interventions
- [11-C]OMAR
- Radiation
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Cognitive Remediation, Computer Skills
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Schizophrenia, Pediatric
- Interventions
- Lumateperone 42 mg, Lumateperone 28 mg
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Hollywood, Florida • Atlanta, Georgia • Decatur, Georgia
- Conditions
- Major Depression, Schizophrenia, Bipolar Disorder, Lung Cancer, Breast Cancer, Head and Neck Cancer, GI Cancer, Cancer
- Interventions
- Proactive Psychiatry Consultation (PPC)
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Schizophrenia Disorders
- Interventions
- Cognitive Behavioral Therapy, TAU
- Behavioral
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Schizophrenia
- Interventions
- Folic Acid, Placebo
- Dietary Supplement · Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2019
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder, Schizophreniform Disorders
- Interventions
- Sublingual film containing Igalmi
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas
- Conditions
- Psychosis
- Interventions
- Omega-3 Long Chain Fatty Acid, Placebo
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 12 Years to 30 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Diego, California • New Haven, Connecticut + 5 more
- Conditions
- Schizophrenia, Delusional Disorder
- Interventions
- Acceptance and Commitment Therapy
- Behavioral
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Schizophrenia, Bipolar I Disorder
- Interventions
- VHX-896 and iloperidone, Iloperidone and VHX-896
- Drug
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 3
- States / cities
- Los Alamitos, California • Gaithersburg, Maryland • Marlton, New Jersey
- Conditions
- Psychosis Associated With Alzheimer's Disease
- Interventions
- ML-007C-MA
- Drug
- Lead sponsor
- MapLight Therapeutics
- Industry
- Eligibility
- 55 Years to 91 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 6
- States / cities
- Anaheim, California • Doral, Florida • Miami, Florida + 2 more
- Conditions
- Tobacco Smoking
- Interventions
- Nicotine Patch, E-cigarette
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Schizophrenia
- Interventions
- OPC-34712
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Miami, Florida • Minneapolis, Minnesota • San Antonio, Texas
- Conditions
- Schizophrenia
- Interventions
- armodafinil, placebo
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 39
- States / cities
- Little Rock, Arkansas • Anaheim, California • Escondido, California + 32 more
- Conditions
- Schizophrenia Spectrum and Other Psychotic Disorders, Cognitive Impairment
- Interventions
- rTMS, Computerized cognitive training
- Device · Behavioral
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Bipolar Disorder, Depression, Mania, Psychosis
- Interventions
- Not listed
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Schizophrenia
- Interventions
- xanomeline and trospium chloride (X/T) therapy
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 20
- States / cities
- Orange, California • San Jose, California • Miami, Florida + 17 more
- Conditions
- Schizophrenia
- Interventions
- xanomeline tartrate, Trospium chloride
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Schizophrenia
- Interventions
- Placebo, Valbenazine
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 442 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Rogers, Arkansas • Anaheim, California + 39 more
- Conditions
- Clinical High Risk, Early Psychosis, First Episode Psychosis
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 12 Years to 29 Years
- Enrollment
- 25,000 participants
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Schizophrenia
- Interventions
- MDMA 40mg, MDMA 80mg, MDMA 120mg
- Drug
- Lead sponsor
- Anya Bershad, MD, PhD
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Schizophrenia
- Interventions
- Magstim Rapid-2 system triggering Magstim Super Rapid system
- Device
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut